Citi Downgrades Regeneron, Citing 'Underappreciated' Risk
December 01, 2017 at 09:57 AM EST
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Monday the failure and discontinuation of two trials for angiopoietin2. Between ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.